Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

Status:
Not yet recruiting

Trial end date:
2024-01-15

Target enrollment:

Participant gender:

Multicenter, phase III, randomized, blinded, controlled, parallel group.

Phase 3

Lyra Therapeutics